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ABSTRACT
INTRODUCTION The morbidity and significant health economic impact associated with the chondral lesion has led to a large
number of strategies for therapeutic neochondrogenesis. The challenge has been to develop techniques that are cost effective
single-stage procedures with minimal surgical trauma that have undergone rigorous preclinical scrutiny and robust reproducible
assessment of effectiveness. A biological repair requires the generation of a cellular and matrix composite with appropriate sig-
nalling for chondrogenic differentiation.
METHODS AND RESULTS A technique was developed that allowed chondrogenic primary (uncultured) cells from bone marrow
aspirate concentrate, combined with a composite hydrophilic and fibrillar matrix to be applied arthroscopically to a site of a
chondral lesion. The construct was tested in vitro and in animal experiments before clinical trials.
Clinical trials involved 60 patients in a prospective study. Symptomatic International Cartilage Repair Society grade 3 and
4a lesions were mapped and treated. Pre- and postoperative clinical assessments showed statistically significant improved out-
comes; Lysholm Knee Scoring Scale (mean 52.8 to > 76.4; P < 0.05) International Knee Documentation Committee (mean 39
to > 79 P < 0.05) and Knee injury and Osteoarthritis Outcome Score (64.5 to >89.2 P < 0.05). Postoperative magnetic
resonance imaging was evaluated morphologically (magnetic resonance observation of cartilage repair tissue, average MOCART
score 72) and qualitatively; the regenerate was comparable to native cartilage.
CONCLUSIONS This technique is effective, affordable, requires no complex tools and delivers a single-stage treatment that is
potentially accessible to any centre capable of performing arthroscopic surgery. Good clinical results were found to be sustained
at five years of follow-up with a regenerate that appears hyaline like using multiple magnetic resonance measures.
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Introduction
The hallmark of tissue engineered therapeutic chondrogen-
esis is the delivery of chondrogenic cells to the articular sur-
face, with a matrix that is either induced by these cells or
delivered alongside them. Despite published successes of a
number of such techniques,1–3 they have not been adopted
widely and, to date, microfracture remains the most prac-
ticed method of biological resurfacing of the joint.4,5 Bar-
riers to the adoption of advanced regenerative techniques
include accessibility of the technique, weakness of evidence,
any additional morbidity associated with the procedure and
the relative cost compared with conventional treatments,
palliation and arthroplasty. It is probable that for new thera-
peutic options to escape the confines of specialist centres, a
robustly evidenced low-cost technique minimising the surgi-
cal insult that is accessible to the mainstream orthopaedic
surgeon should be developed. Such a development should
be evidence based from concept to application.
240 Ann R Coll Surg Engl 2018; 100: 240–246
KNEE SURGERY
Ann R Coll Surg Engl 2018; 100: 240–246
doi 10.1308/rcsann.2017.0223
Background
Cartilage injuries are common and are naturally progres-
sive with limited potential for intrinsic repair.6,7 Cartilage
has evolved of into a tissue with properties that allow effi-
cient force transfer and a frictionless surface necessary to
prevent thermal and mechanical destruction of the tissue
when subjected to physiological forces.8,9 The property of
the cartilage matrix that makes this possible is a highly
hydrophilic matrix, constrained within fibrillar collagen II
arcades.8,10 This, combined with multiple methods of lubri-
cation, yields a specialised tissue,8 which is produced and
maintained by differentiated cells able to function in the
absence of a vascular supply; such vasculature would not
tolerate the forces that the tissue experiences. Damage to
this structure triggers two vicious circles that lead to pro-
gressive disease. First, the loss of structural integrity
causes the tissue to be less mechanically efficient, with
consequence that the tissue becomes subject to further
damage.9,11 Second, the tissue damage leads to an inflam-
matory response whose catabolic cascade through the
release of metalloproteinases disrupts the fibrillar architec-
ture, with loss of constraint of the hydrophilic hyaluronic
acid and glycoconjugates and further structural damage.12
The development of subchondral sclerosis and cysts may
further complicate the biology and the mechanics of the
overlying damaged cartilage.13
The implication, evidenced by even the earliest observa-
tions of articular cartilage lesions, is that the biological
equilibrium that exists in articular cartilage is very vulner-
able to any mechanical or biochemical disruption and,
once exceeding the functional capacity of the chondrogenic
cells, leads to progressive failure of the tissue. Three things
are required for effective chondrogenesis: cells with the
potential to produce and maintain appropriate matrix, a
scaffold that supports the cells and a subchondral plate
with suitable mechanical and vascular properties to sustain
the growing construct.
Many attempts at reversing damage to articular cartilage
have been developed. They may be classified by the com-
ponent of the tissue that is involved in initiating the regen-
erative. Chondrostimulation may introduce cells to the
surface that may form articular cartilage, usually fibrocarti-
lage, lacking in any hydrophilic matrix.14 This can be
improved if the matrix produced by the chondrogenic cell
can be contained within a ‘bioactive chamber’.15 An acellu-
lar fibrillar scaffold using collagen (almost always type I)
has also been found to be effective.16 Collagen type I, while
readily available and widely used, may not be the optimal
scaffold.17
Delivery of chondrogenic cells transforms the repair to
an active process. The now classical autologous chondro-
cyte implantation,2 intensifies the chondrotypical cellular
component by the use of cultured chondrocytes. The use of
periosteal patches over the repair site have been used but
the additional cellular component of these patches appears
to provide no benefit.18 Cultured chondrocytes may dedif-
ferentiate in monolayer culture. Characterisation techni-
ques selecting cells for their phenotypic behaviour to
counter this dedifferentiation has been shown to improve
results but the mortality of differentiated cells is a limiting
factor.19 Bone marrow-derived stems cells offer the poten-
tial for delivering a source of chondrogenic cells after
preconditioning.20
Three-dimensional scaffolds further enhance the matrix
composition of the regenerated tissue. Techniques combin-
ing matrix and cells represent a progression in the evolu-
tion of chondroregenerative therapies.21,22 Experiments
with nonfibrillar–protein hydrogel matrices also suggest
that a hydrophilic component may be important.23,24
Despite such a proliferation of techniques, few have
achieved the sustained acceptance required to become a
mainstream therapeutic offering for patients with chondral
lesions to replace microfracture.25 Many factors may
account for this situation: the surgical trauma of a proce-
dure requiring arthrotomy, the need for a two-stage proce-
dure, the expense of the culture process despite longer-
term economic benefits,26,27 relatively small numbers in
trials and the availability of an alternative definitive thera-
peutic options in the form of replacement arthroplasty.
Aims
The goal has been to develop a technique that is robust,
single stage, minimally invasive, cost effective and accept-
able to both patient and clinician. Robustness relies on
having a vertical translation of research starting a logically
derived concept, tested in in-vitro studies, applied in in-
vivo standardised animal models and delivered to clinical
practice after a sound ethical review. The expense of cul-
ture processing should be avoided. The approach should
be minimally invasive and the surgical trauma should not
exceed conventional microfracture. The repair construct,
as stated earlier, should combine chondrogenic cells,
hydrophilic matrix and fibrillar protein constraint. The
composite should be adherent and should have mechanical
integrity.
Mesenchymal cell-induced chondrogenesis (MCIC) is a
technique that has been developed with these objectives.
Three factors enabled the development of this technique.
Concentrating chondrogenic cells using fractionation cen-
trifugation enables intensification without culture.28 The
use of fibrin glue allows the formation of an adhesive gel
that can act as a carrier for both cells and adjuvant matrix
components.16 Arthroscopic application of this gel is
enabled by the use of carbon dioxide insufflation and dry
arthroscopy. While the use dry arthroscopy has been found
to be effective,29 a modification using CO2 insufflation
allowed improved delivery of the composite construct even
against gravity.
Assessment of repair may be symptomatic, functional or
morphological. While it is expected that symptomatic relief
is what is being targeted with treatments, some assessment
of the regenerate itself is important. While an invasive his-
tological assessment may cause some ethical concerns,
high resolution magnetic resonance imaging (MRI) techni-
ques can non-invasively evaluate the repair tissue.30
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In vitro tests
Primary cells with chondrogenic differentiation potential
can be derived from bone marrow aspirate. These cells
can be selectively concentrated by centrifugal fractionation.
The bone marrow aspirate concentrate (BMAC) yields an
increase of nucleated cell density by a factor of 5.8 (± 2.74
standard error; n = 10) and an increase in the number of
colony-forming units by 5.23 times (Fig 1). The levels of
vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF) AB, stromal cell-derived factor 1
alpha (SDF1a) and transforming growth factor beta 1
(TGFb1) in the supernatants were measured by enzyme-
linked immunosorbent assay. In the BMAC group, the
VEGF, PDGF AB, SDF1a and TGFb1 was significantly
increased compared with bone marrow. The mean concen-
tration of VEGF was 318.33 ± 249.93 pg/ml in bone marrow
and 2203.33 ± 855.91 pg/ml in BMAC. The mean concen-
tration of PDGF AB was 658.33 ± 456.53 pg/ml in bone
marrow and 4438.33 ± 2695.18 pg/ml in BMAC; the mean
concentration of SDF1a was 1650.00 ± 1866.28 pg/ml in
bone marrow and 24581.67 ± 18198.13 pg/ml in BMAC, the
mean concentration of TGFb1 was 13.67 ± 22.70 pg/ml in
bone marrow and 190.00 ± 119.33 pg/ml in BMAC. Surface
markers were tested using fluorescence-activated cell sort-
ing analysis demonstrating an expression pattern consis-
tent with mesenchymal stem cells (Fig 2).
Two commercially available matrix agents with approval
for human use have been chosen for the composite micro-
scaffold. Hyaluronic acid provides a hydrophilic matrix and
fibrinogen forms the fibrillar adhesive component that
undergoes phase change from liquid to hydrogel under
controllable physiological conditions. The cell matrix com-
posite has good adhesion and structural integrity, while
fluorescent dye staining demonstrates viability of nucleated
cells of over 90% (Fig 3). Phenotypical behaviour was eval-
uated using cell morphology and in vitro production of col-
lagen type II. Adhesion of the construct required an
irregular surface.
Preclinical tests
We used a standard animal model for cartilage repair.
Adult New Zealand white rabbits with a trochlear lesion
were treated with microfracture (M group, control), micro-
fracture with acellular matrix (MH group), microfracture
with matrix plus BMAC (MBH group). After retrieval of
these lesions at six weeks, the repair tissue was investi-
gated with Masson trichrome staining and immunohisto-
chemistry for collagen types I and II. The results with
BMAC and the composite microscaffold exceed controls
and microscaffold without cells, and are comparable to
those found in other studies (Fig 4).
Clinical protocol
Clinical trial was performed in UK and the comparative
clinical data were supported from the South Korean cohort.
Patient selection criteria were defined and thorough ethical
review was undertaken, scrutinised by governance teams.
Patients were recruited after counselling and a robust
pathway for clinical support and follow-up was in place.
Assessment was with standard symptom scores and
delayed gadolinium-enhanced MRI of cartilage (dGEMRIC)
and T2 mapping of chondral lesions. This was a prospec-
tive trial with no synchronous controls, comparing sympto-
matic and functional scoring for patients prior to surgery.
The study included 60 patients (38 male and 22 female)
(mean age 44.4 years, range 19–61 years) with an average
chondral lesion size of 3.8 (Table 1). All patients were fol-
lowed-up for five years.
One prime consideration was that the surgical trauma
should not significantly exceed the trauma induced by the
well-established conventional microfracture. This implied
an arthroscopic procedure. Delivering a gel matrix to the
articular surface with fluid irrigation would be naturally
challenging, so the arthroscopic procedure is adapted to
use the CO2 insufflation employed in laparoscopic surgery
after the initial debridement and preparation of the lesion.
The surgical workflow is initially similar to conventional
microfracture, including:
> bone marrow aspiration from the ipsilateral iliac crest
> evaluation of the joint condition and mapping of
lesions pre-debridement during initial joint survey
> debridement of any degenerate menisci and the unsta-
ble portion of the articular cartilage lesions
> reduction of subchondral sclerosis
> microfracture and mapping of the post debridement
lesion
> washout of any debris induced
> CO2 insufflation and drying of the lesions to be treated
> application of the composite gel to the surface.
For the purposes of the study microfracture was deemed
necessary to provide shear stability of the construct and
this was tested by cycling the joint through a range of
motion (Fig 5).
The postoperative protocol was initial continuous pas-
sive motion for four hours, followed by either partial
(a) (b) (c)
Figure 1 Crystal violet-stained colony forming units-fibroblast.
Representative samples are shown. a) The bone marrow sample
was a small number of variable sized colonies. b) The bone
marrow aspirate concentrate (BMAC) sample was many colonies
more than bone marrow, which varies widely in size, cell den-
sity and cell number. c) A BMAC sample of a single-medium
sized colony (x 12.5 magnification image of a)
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Figure 2 Flow cytometry analysis of bone marrow aspirate concentrate (BMAC) and bone marrow (BM). Nucleated cells of isolation
labelled with antibodies against the indicated antigens and analyzed by flow cytometry. Representative histograms are displayed. On the y
axis is the cell count (the cells were gated mononuclear cells) and on the x axis is the fluorescence intensity in a log (100–105) scale.
The isotype control is shown as a red line histogram
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weight bearing but allowing full range of motion for tibio-
femoral lesions or mobilising in a brace when load bearing
with full weight bearing allowed for patellofemoral lesions
for six weeks.
Results of clinical trials
Follow-up included symptom and functional scoring tests
using International Knee Documentation Committee, Knee
injury and Osteoarthritis Outcome Score and Lysholm
Knee Scoring Scale.3 Six-monthly MRI follow-up was
required for evaluation using repair scores in the trial
phase. Qualitative and quantitative MRI scans were ana-
lysed by an independent radiologist with a special interest
in mapping of cartilage defects and repair tissue. The
Figure 3 Biochemical staining of the sections obtained from
bone marrow aspirate concentrate gel beads. Fluorescent dye
staining of the sections taken from beads incubated for four
days (original magnification × 40). Viable cells appeared green
and dead cells were red, when they were stained with calcein
acetoxymethyl ester and ethidium homodimer, respectively
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4 Photomicrograph of the section of regenerated carti-
lage of the microfracture with matrix plus bone marrow aspirate
concentrate group with a) Masson trichrome staining; b) immu-
nohistochemical staining with anti-collagen type I antibody; and
c) immunohistochemical staining with anti-collagen type II anti-
body and the microfracture with acellular matrix group (d–f);
and microfracture group (x 40) (g–i), respectively
Table 1 Demographic information (N = 60).
Variable Mean ± SE (range) n (%)
Age (year) 44.4 ± 1.7 (19–61)
Lesion size (cm2) 3.8 ± 0.2 (2–9)
Chondral lesions (n)
1 38 (63.3)
2 14 (23.3)
3 or more 8 (13.3)
Location (multi-responses):
Medial femoral condyle 39 (65)
Trochlea 14 (23.3)
Lateral femoral condyle 12 (20)
Lateral tibial plateau 10 (16.7)
Patella 9 (15)
Medial tibial plateau 6 (10)
SE, standard error
(a) (b)
(c) (d)
Figure 5 Mesenchymal cell-induced chondrogenesis proce-
dure. a) Arthroscopic evaluation of knee joint and cartilage
lesion; b) lesion preparation and microfracture; c) bone marrow
aspirate concentrate and gel scaffold injection under CO2 infla-
tion; d) second-look arthroscopic findings after two years
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results are shown in Fig 6 and Table 2. Statistically signifi-
cant improvement in symptom scores were seen in all
scoring systems.
Improvements were seen on MRI using both qualitative
and quantitative (T2*-mapping and dGEMRIC) assess-
ments. For the structured morphological assessment, the
magnetic resonance observation of cartilage repair tissue
(MOCART) score was used for postoperative magnetic res-
onance examinations. A MOCART score of 0 represents the
worst possible result and 100 the best possible MRI out-
come. A mean MOCART of 72 ± 21 (mean ± standard devia-
tion, SD, standard error 1.4), T2*-mapping and dGEMRIC
scores comparing regenerate with adjacent native articular
cartilage (relaxation times 29.2 ± 8.5 and 29.9 ± 6.3 (mean
± SD) respectively, over the first two-year period of the fol-
low-up showed the regenerate to be hyaline-like in signal
(Table 2). The MOCART scores show improvement
continues over the two-year period of magnetic resonance
assessment.
The financial cost of a procedure is a factor that often
determines acceptability of regenerative techniques to
health service providers. Tables 3 and 4 show representa-
tive costs converted to US dollars for comparison. A signifi-
cant contributor to the cost of MCIC had been the need for
three MRI scans for the purposes of this study. The two
centres for the trial have different methods of determining
the cost of a procedure. For the UK cohort, costs were
itemised and calculated by service provider for this partic-
ular procedure, and compared with standard tariffs for rou-
tine joint replacement and arthroscopy plus microfracture
for NHS patients by the same provider. The costs in South
Korea have many more confounding variables.
The mean surgical time reduced from 55 minutes to 35
minutes over the five years of the initial trial. The serious
complications rate is comparable to that of arthroscopic
procedures; in our trials, there were no serious complica-
tions in these arthroscopic procedures.
100
90
80
70
60
50
40
30
Pre-OP 6 month 1 year 2 year 3 year 4 year 5 year
IKDC
KOOS
Lysholm
Figure 6 Summary of clinical outcome. All the scores showed
significant improvement from preoperative evaluation to 60-
month follow-up. KOOS, Knee injury and Osteoarthritis Out-
come Score; IKDC, International Knee Documentation
Committee
Table 2 Summary of clinical and radiological outcome (N = 60).
Variable Preoperative (a) 6-month (b) 1-year (c) 2-year (d) 3-year (e) 4-year (f) 5-year (g) P (post hoc)
Mean (SE)
IKDC 39.0 (0.6) 68.0 (0.9) 72.0 (0.9) 82.0 (1.0) 83.0 (1) 81.0 (1.2) 79.0 (1.1) < .001i (a < b, c, d, e, f, g)ii
KOOS 64.5 (1.3) 78.0 (1.1) 83.5 (0.9) 92.2 (0.7) 90.6 (0.7) 88.4 (0.7) 89.2 (0.7) < .001i (a < b, c, d, e, f, g)ii
Lysholm 52.8 (1.2) 62.6 (0.9) 76.7 (1.2) 80.8 (1.3) 79.6 (1.4) 79.8 (1.3) 76.4 (1.1) < .001i (a < b, c, d, e, f, g)ii
MOCART 60.0 (1.2) 66.0 (1.3) 72.0 (1.4) < .001i (b < c < d)b
T2* mapping 29.0 (0.7) 29.2 (0.7) < .001iii
IKDC, International Knee Documentation Committee; KOOS, Knee injury and Osteoarthritis Outcome Score; MOCART, magnetic resonance
observation of cartilage repair tissue; SE, standard error.
i Greenhouse–Geisser
ii Significant different were compared by Bonferroni test following one-way repeated-measures analysis of variance, with significant difference
at P < 0.05.
iii Paired t test
Table 3 Comparison of costs according to treatment
methods
Costs South Korean Cohort
Item MCIC TKR
Average hospital fee per patient $4,713.6 $6,754.0
Corporate contribution $3,100.4 $4,546.4
Personal contribution $1,613.2 $2,2076
Special doctor fee $553.0 $658.4
The exchange rate for the hospital fees of Korean won for US
dollars was 1,095.04 won.
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Conclusions
MCIC has benefitted from the thorough review of existing
methods of chondroregenerative therapeutic options and
their limitations. A vertical translational methodology was
followed from developing and testing the construct in cul-
ture, followed by representative standardised animal stud-
ies before proceeding to clinical studies. The procedure
has a shallow learning curve being an evolutionary pro-
gression of other well-established techniques. Surgical
trauma is minimal and this may lead to low complication
rates compared with open procedures in other studies. The
biggest hurdle limiting acceptability of chondroregenera-
tive techniques remains the health economic justification
of an expensive procedure which may, for many patients,
merely delay implant arthroplasty rather than replacing it.
This procedure is much more cost effective than other
regenerative techniques (partly by using primary cells
rather than relying on cell culture), to the extent that it
may be a reasonable alternative to arthroplasty even in
older patient with symptomatic single compartment
lesions.
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